Timely Answer:
They no longer have that board member who brought only financial expertise, who did not agree with the strategy moving forward. It was not stated by the company what that strategy was.
It was postulated that he preferred the stem cell business model to going after alternative revenue streams. No proof of that. Meaningless as the company is still more than capable to do anything stem cell related they choose.
Long term the real money remains in women's health, database, oncology, etc...but to benefit from saving lives during a public health crisis (if happening) is not a negative.
News 
Market Data 
Discover 
